(Q37486605)

20 August 2017

1 reference

title

Update on oral antiplatelet therapy: principles, problems and promises (English)

1 reference

20 August 2017

author

Steen Dalby Kristensen

series ordinal

2

object named as

Steen D Kristensen

1 reference

20 August 2017

Erik L Grove

1

1 reference

20 August 2017

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

247-258

1 reference

Biology and pharmacology of the platelet P2Y12 receptor

20 August 2017

cites work

1 reference

The platelet polymorphism PlA2 is a genetic risk factor for myocardial infarction

21 January 2018

1 reference

Platelets: developmental biology, physiology, and translatable platforms for preclinical investigation and drug development.

21 January 2018

1 reference

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis

21 January 2018

1 reference

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

Dual antiplatelet agent failure: a new syndrome or clinical nonentity?

21 January 2018

1 reference

Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials

21 January 2018

1 reference

Variable platelet response to aspirin and clopidogrel in atherothrombotic disease

21 January 2018

1 reference

Aspirin resistance: myth or major problem?

21 January 2018

1 reference

Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Wo

21 January 2018

1 reference

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis

21 January 2018

1 reference

Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance

21 January 2018

1 reference

Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration

21 January 2018

1 reference

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin

21 January 2018

1 reference

Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets

21 January 2018

1 reference

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

21 January 2018

1 reference

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

Clopidogrel in acute coronary syndrome: to genotype or not?

21 January 2018

1 reference

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

21 January 2018

1 reference

The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies.

21 January 2018

1 reference

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans

21 January 2018

1 reference

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?).

21 January 2018

1 reference

Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thro

21 January 2018

1 reference

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

21 January 2018

1 reference

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

21 January 2018

1 reference

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

Coronary stent restenosis in patients treated with cilostazol

21 January 2018

1 reference

Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention

21 January 2018

1 reference

A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.

21 January 2018

1 reference

Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study

21 January 2018

1 reference

Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease

21 January 2018

1 reference

Highlights of the 56th Annual Scientific Session of the American College of Cardiology, March 24-27, 2007. ACC.07 and i2 Summit Highlights: A Conversation With the Experts.

21 January 2018

1 reference

Oral glycoprotein IIb/IIIa inhibitors: why don't they work?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FCA.09.10

1 reference

20 August 2017

1 reference